Cargando…

Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report

INTRODUCTION: Globally, the coronavirus disease 2019 (COVID-19) is still spreading rapidly. At present, there are no specifically approved therapeutic agents or vaccines for its treatment. Previous studies have shown that the convalescent plasma therapy (CPT) is effective in patients with COVID-19....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Min, Yang, Xiaohong, Yang, Fang, Zhu, Xinxin, Sun, Zhibing, Bao, Peiling, Yan, Yimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478552/
https://www.ncbi.nlm.nih.gov/pubmed/32898996
http://dx.doi.org/10.1097/MD.0000000000021596
_version_ 1783580077662928896
author Wang, Min
Yang, Xiaohong
Yang, Fang
Zhu, Xinxin
Sun, Zhibing
Bao, Peiling
Yan, Yimin
author_facet Wang, Min
Yang, Xiaohong
Yang, Fang
Zhu, Xinxin
Sun, Zhibing
Bao, Peiling
Yan, Yimin
author_sort Wang, Min
collection PubMed
description INTRODUCTION: Globally, the coronavirus disease 2019 (COVID-19) is still spreading rapidly. At present, there are no specifically approved therapeutic agents or vaccines for its treatment. Previous studies have shown that the convalescent plasma therapy (CPT) is effective in patients with COVID-19. However, its efficacy in patients with persistently positive nucleic acid test is unknown. PATIENT CONCERNS: In this report, we present the clinical data of 5 critically ill COVID-19 patients admitted, between January 16 and February 26, 2020, in intensive care unit of Xiaogan Central Hospital. DIAGNOSIS AND INTERVENTIONS: All these patients had a persistently positive nucleic acid test and received CPT. All 5 patients had severe respiratory failure, and thus, required invasive mechanical ventilation. The median time from the onset of symptoms to initiating the CPT was 37 (Interquartile range, 34-44) days. OUTCOMES: Only 2 patients were cured and subsequently discharged, while 3 patients succumbed due to multiple organ failure. CONCLUSION: The time of initiating the CPT may be an important factor affecting its efficacy, and its therapeutic effect in the treatment of COVID-19, in the late stage, is limited.
format Online
Article
Text
id pubmed-7478552
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-74785522020-09-16 Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report Wang, Min Yang, Xiaohong Yang, Fang Zhu, Xinxin Sun, Zhibing Bao, Peiling Yan, Yimin Medicine (Baltimore) 4900 INTRODUCTION: Globally, the coronavirus disease 2019 (COVID-19) is still spreading rapidly. At present, there are no specifically approved therapeutic agents or vaccines for its treatment. Previous studies have shown that the convalescent plasma therapy (CPT) is effective in patients with COVID-19. However, its efficacy in patients with persistently positive nucleic acid test is unknown. PATIENT CONCERNS: In this report, we present the clinical data of 5 critically ill COVID-19 patients admitted, between January 16 and February 26, 2020, in intensive care unit of Xiaogan Central Hospital. DIAGNOSIS AND INTERVENTIONS: All these patients had a persistently positive nucleic acid test and received CPT. All 5 patients had severe respiratory failure, and thus, required invasive mechanical ventilation. The median time from the onset of symptoms to initiating the CPT was 37 (Interquartile range, 34-44) days. OUTCOMES: Only 2 patients were cured and subsequently discharged, while 3 patients succumbed due to multiple organ failure. CONCLUSION: The time of initiating the CPT may be an important factor affecting its efficacy, and its therapeutic effect in the treatment of COVID-19, in the late stage, is limited. Lippincott Williams & Wilkins 2020-09-04 /pmc/articles/PMC7478552/ /pubmed/32898996 http://dx.doi.org/10.1097/MD.0000000000021596 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle 4900
Wang, Min
Yang, Xiaohong
Yang, Fang
Zhu, Xinxin
Sun, Zhibing
Bao, Peiling
Yan, Yimin
Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report
title Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report
title_full Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report
title_fullStr Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report
title_full_unstemmed Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report
title_short Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report
title_sort convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report
topic 4900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478552/
https://www.ncbi.nlm.nih.gov/pubmed/32898996
http://dx.doi.org/10.1097/MD.0000000000021596
work_keys_str_mv AT wangmin convalescentplasmatherapyincriticallyillcoronavirusdisease2019patientswithpersistentlypositivenucleicacidtestcaseseriesreport
AT yangxiaohong convalescentplasmatherapyincriticallyillcoronavirusdisease2019patientswithpersistentlypositivenucleicacidtestcaseseriesreport
AT yangfang convalescentplasmatherapyincriticallyillcoronavirusdisease2019patientswithpersistentlypositivenucleicacidtestcaseseriesreport
AT zhuxinxin convalescentplasmatherapyincriticallyillcoronavirusdisease2019patientswithpersistentlypositivenucleicacidtestcaseseriesreport
AT sunzhibing convalescentplasmatherapyincriticallyillcoronavirusdisease2019patientswithpersistentlypositivenucleicacidtestcaseseriesreport
AT baopeiling convalescentplasmatherapyincriticallyillcoronavirusdisease2019patientswithpersistentlypositivenucleicacidtestcaseseriesreport
AT yanyimin convalescentplasmatherapyincriticallyillcoronavirusdisease2019patientswithpersistentlypositivenucleicacidtestcaseseriesreport